Article details
CNBC's Jim Cramer highlighted that Apple (AAPL) and Eli Lilly (LLY) still have significant growth potential following strong post-earnings rallies. Both stocks surged after reporting better-than-expected quarterly results, driven by robust demand for Apple's services and Lilly's diabetes drug Mounjaro. Cramer emphasized that these companies' fundamentals remain strong, with Apple benefiting from its ecosystem and Lilly capitalizing on its pharmaceutical innovation. For markets, this signals continued investor confidence in tech and healthcare sectors, which are key drivers of the S&P 500. Traders should monitor earnings momentum and broader market sentiment for potential follow-through. Looking ahead, the focus will be on whether these stocks can sustain their upward trajectory amid macroeconomic uncertainties and sector-specific challenges.
